Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating. Akari Therapeutics’ rating score has improved by 50% in the last three months as a result of various analysts’ upgrades and downgrades.
Analysts have set a 1 year consensus price target of $2.50 for the company and are predicting that the company will post ($1.00) EPS for the current quarter, according to Zacks. Zacks has also assigned Akari Therapeutics an industry rank of 179 out of 265 based on the ratings given to related companies.
A number of analysts have recently commented on the company. Zacks Investment Research cut Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 16th. ValuEngine upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th.
Akari Therapeutics (AKTX) traded down $0.01 during trading on Monday, hitting $3.59. The stock had a trading volume of 327,400 shares, compared to its average volume of 191,600. The stock has a market capitalization of $54.77, a PE ratio of -1.34 and a beta of -8.64. Akari Therapeutics has a 1-year low of $3.18 and a 1-year high of $22.20.
Akari Therapeutics (NASDAQ:AKTX) last posted its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.00) by $0.91. equities analysts predict that Akari Therapeutics will post -2 earnings per share for the current fiscal year.
About Akari Therapeutics
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.